BioSpace News Archive

IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers (“IN8bio” or the “Company”), today announced that William Ho, Chief Executive Officer of IN8bio, will present at the 3rd Annual Evercore ISI HealthCONx Conference

Travere Therapeutics announced completion of patient enrollment in the Phase 3 DUPLEX Study.

OmniGuide Holding, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announces the commercial launch of LISA Laser Urology Holmium and Thulium Fibers produced in the USA.

Surgalign Holdings, Inc. (Nasdaq: SRGA), a leading global pure-play spine company focused on advancing spine surgery and improving patient outcomes, today announced that the management team will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Thursday, December 3, 2020.

Pivotal Phase 3 trial in United Kingdom completes enrollment Phase 2b efficacy trial in South Africa completes enrollment U.S./Mexico Phase 3 trial expected to begin in the coming weeks

Advanced Healthcare IT AI Solution Can Speed Up Clinical Response and Help Increase Diagnostic Confidence to Take Patient Care to the Next Level

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the 2020 Evercore ISI HealthCONx Conference. The conference will be simultaneously webcast over the Internet. Dr. Tang is scheduled to speak on December 3, 2020, at approximately 9:40 AM Eastern Standard Time (6:40 AM Pacifi

OraSure Technologies, Inc., a leader in the fight against HIV, announced its plans to commemorate World AIDS Day.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the launch of Anemia ID, a program providing no-cost genetic testing for patients with suspected hereditary anemias

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday, December 5, 2020, at 2:00 p.m. ET. The event will take place following a poster presentation featuring the first clinical data from the Company’s Phase 1 trial evaluating IGM-2323 at the 62nd American Soci